Hayashi Manabu, Abe Kazumichi, Sugaya Tatsuro, Takahata Yosuke, Fujita Masashi, Takahashi Atsushi, Ohira Hiromasa
Department of Gastroenterology, Fukushima Medical University, Fukushima, Japan.
Jpn J Clin Oncol. 2024 Jan 7;54(1):62-69. doi: 10.1093/jjco/hyad132.
The prediction of prognosis in hepatocellular carcinoma patients is important for switching treatment. The association between circulating growth arrest-specific 6 levels and prognosis in hepatocellular carcinoma patients is unknown.
We retrospectively analysed the association between serum growth arrest-specific 6 levels and clinical findings in 132 patients with hepatocellular carcinoma. Serum growth arrest-specific 6 levels were measured using enzyme-linked immunosorbent assay.
Amongst 132 patients, the Barcelona Clinic Liver Cancer stage was classified as 0, A, B, C and D in 19, 48, 41, 18 and 6 patients, respectively. Serum growth arrest-specific 6 levels in hepatocellular carcinoma patients were higher than those in healthy controls (28.4 ng/mL vs. 19.6 ng/mL, P < 0.001), and growth arrest-specific 6 levels were positively correlated with soluble Axl levels. In the entire cohort, high growth arrest-specific 6 levels were associated with a shorter survival period (hazard ratio: 1.78 per 20 ng/mL, 95% confidence interval: 1.01-3.16, P = 0.045). In early and intermediate-stage hepatocellular carcinoma patients treated with transcatheter arterial chemoembolization (n = 59), we determined a cut-off value of 36.4 ng/mL based on the receiver operating characteristic curve to predict death within 3 years, and high growth arrest-specific 6 levels were associated with a high cumulative incidence of portal vein tumour thrombosis (Gray's test: P = 0.010) and shorter overall survival (log-rank: P = 0.005).
Serum growth arrest-specific 6 levels were associated with prognosis in hepatocellular carcinoma patients. In early and intermediate-stage hepatocellular carcinoma patients who underwent transcatheter arterial chemoembolization, high growth arrest-specific 6 levels were associated with a high incidence of portal vein tumour thrombosis. Circulating growth arrest-specific 6 levels may be a useful prognostic marker in hepatocellular carcinoma patients.
预测肝细胞癌患者的预后对于调整治疗方案很重要。循环中生长停滞特异性蛋白6（Gas6）水平与肝细胞癌患者预后之间的关联尚不清楚。
我们回顾性分析了132例肝细胞癌患者血清Gas6水平与临床特征之间的关联。采用酶联免疫吸附测定法检测血清Gas6水平。
132例患者中，巴塞罗那临床肝癌分期为0期、A期、B期、C期和D期的分别有19例、48例、41例、18例和6例。肝细胞癌患者血清Gas6水平高于健康对照者（28.4 ng/mL对19.6 ng/mL，P<0.001），且Gas6水平与可溶性Axl水平呈正相关。在整个队列中，高Gas6水平与较短生存期相关（风险比：每20 ng/mL为1.78，95%置信区间：1.01 - 3.16，P = 0.045）。在接受经动脉化疗栓塞术治疗的早期和中期肝细胞癌患者（n = 59）中，根据受试者工作特征曲线确定预测3年内死亡的临界值为36.4 ng/mL，高Gas6水平与门静脉肿瘤血栓形成的高累积发生率相关（Gray检验：P = 0.010）和较短的总生存期（对数秩检验：P = 0.005）。
血清Gas6水平与肝细胞癌患者的预后相关。在接受经动脉化疗栓塞术的早期和中期肝细胞癌患者中，高Gas6水平与门静脉肿瘤血栓形成的高发生率相关。循环Gas6水平可能是肝细胞癌患者有用的预后标志物。
